Table 2.
Sample size, mean value, and standard deviation for completers plus imputed and completers for the comparison placebo vs reboxetine. The number of LOCF‐imputed and missing outcomes is also given
| id | Treatment | LOCF Analysis | Completers | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SMD | Sample | Mean | SD | LOCF, % | SMD | Sample | Mean | SD | Missing, % | ||
| (95% CI) | Size | (95% CI) | Size | ||||||||
| Versiani2000 | Reboxetine | −1.42 | 28 | 12,60 | 10,30 | 4(14%) | −0.70 | 22 | 10,10 | 8,20 | 0(0%) |
| (Study 091) | Placebo | (−2.01,−0.84) | 28 | 29,50 | 13,30 | 16(57%) | (−1.47,0.07) | 10 | 16,30 | 10,20 | 0(0%) |
| Study 032a | Reboxetine | 0.12 | 22 | 17,18 | 4,75 | 7(32%) | 0.22 | 17 | 16,59 | 4,73 | 2(12%) |
| (CTN032‐ | Placebo | (−0.46,0.69) | 25 | 16,6 | 5,14 | 5(20%) | (−0.42,0.87) | 21 | 15,52 | 4,78 | 1(5%) |
| FCE20124) | |||||||||||
| Study 015 | Reboxetine | −0.19 | 110 | 14,04 | 9,22 | 23(21%) | −0.24 | 89 | 11,26 | 7,17 | 2(2%) |
| Placebo | (−0.45,0.08) | 111 | 15,8 | 9,58 | 26(23%) | (−0.54,0.06) | 87 | 13,08 | 8,06 | 1(1%) | |
| Bosc1997a | Reboxetine | −0.57 | 126 | −13,45 | 8,45 | 38(30%) | NA | 88 | NA | NA | 0(0%) |
| (Study 014 ‐ | Placebo | (−0.82,−0.32) | 128 | −8,64 | 8,45 | 52(41%) | 76 | NA | NA | 0(0%) | |
| Andreoli2002) | |||||||||||
| Ban1998 | Reboxetine | −0.61 | 81 | 11,60 | 7,64 | 8(10%) | −0.69 | 73 | 10,40 | 6,32 | 3 (4%) |
| (Study 008) | Placebo | (−0.93,−0.30) | 83 | 16,68 | 8,87 | 10 (12%) | (−1.02,−0.36) | 73 | 15,52 | 8,37 | 2(3%) |
| Study 049 | Reboxetine | −0.18 | 101 | −9,30 | 5,44 | 37(37%) | −0.19 | 71 | −11,40 | 10,00 | 6(8%) |
| Placebo | (−0.46,0.09) | 101 | −8,30 | 5,44 | 23(23%) | (−0.51,0.13) | 81 | −9,50 | 10,00 | 4(5%) | |
| Study 045 | Reboxetine | 0.21 | 174 | −9,56 | 8,48 | 63(36%) | 0.06 | 119 | −13,32 | 9,96 | 12(10%) |
| Placebo | (−0.05,0.46) | 86 | −11,30 | 8,45 | 20(23%) | (−0.24,0.36) | 68 | −13,90 | 10,00 | 1(1%) | |
| Clayton2003 | Reboxetine | 0.04 | 144 | −10,80 | 8,45 | 63(44%) | 0.08 | 90 | −13,30 | 10,00 | 6(7%) |
| (Study 050) | Placebo | (−0.20,0.27) | 143 | −11,10 | 8,45 | 60(42%) | (−0.21,0.37) | 89 | −14,10 | 10,00 | 7(8%) |
| M/2020/0046 | Reboxetine | 0 | 252 | −11,50 | 8,45 | 67(27%) | −0.03 | 205 | −12,70 | 10,00 | 13(6%) |
| (Study 046) | Placebo | (−0.18,0.18) | 247 | −11,50 | 8,45 | 40(16%) | (−0.22,0.16) | 221 | −12,40 | 10,00 | 10(5%) |
| M/2020/0047 | Reboxetine | −0.13 | 238 | −11,00 | 6,91 | 69(29%) | −0.10 | 189 | −12,30 | 10,00 | 20(11%) |
| (Study 047) | Placebo | (−0.31,0.05) | 239 | −10,10 | 7,27 | 58(24%) | (−0.30,0.10) | 200 | −11,30 | 10,00 | 15(8%) |
| Studie009 | Reboxetine | −0.08 | 24 | 14.38 | 8,94 | 6(25%) | −0.31 | 18 | 12.56 | 8,30 | 2(11%) |
| (CTN009‐ | Placebo | (−0.65,0.49) | 23 | 15.09 | 8,52 | 7(30%) | (−0.98,0.36) | 17 | 15.12 | 8,28 | 1(6%) |
| FCE20124) | |||||||||||
| POOLED RESULTS | −0.24 | Heterogeneity SD = 0.29 | −0.15 | Heterogeneity SD = 0.17 | |||||||
| RANDOM EFFECTS | (−0.43,−0.05) | (−0.30,0.00) | |||||||||
Abbreviations: CI, confidence interval; LOCF, last observation carried forward; SD, standard deviation; SMD, standardized mean difference.